Key result
VEGF165 gene therapy increases myofibroblast differentiation ~3-fold and cuts proliferation in rat myocardial infarcts.
Why the study?
Does VEGF165 gene transfer improve extracellular matrix remodeling in Wistar rats after acute myocardial infarction?
Does VEGF165 gene transfer improve extracellular matrix remodeling in Wistar rats after acute myocardial infarction?
VEGF165 gene transfer promotes tissue differentiation and may provide a protective effect against adverse extracellular matrix remodeling after acute myocardial infarction in a preclinical model.
Answers are grounded in this paper and cite their sources.
May support VEGF165 for post-MI remodeling in rats; leaves open translation to clinical use.
OBJECTIVE: Evaluate the effects of VEGF165 gene transfer in the process of remodeling of the extracellular matrix after an acute myocardial infarct. METHODS: Wistar rats were submitted to myocardial infarction, after the ligation of the left descending artery, and the left ventricle ejection fraction was used to classify the infarcts into large and small. The animals were divided into groups of ten, according to the size of infarcted area (large or small), and received or not VEGF165 treatment. Evaluation of different markers was performed using immunohistochemistry and digital quantification. The primary antibodies used in the analysis were anti-fibronectin, anti-vimentin, anti-CD44, anti-E-cadherin, anti-CD24, anti-alpha-1-actin, and anti-PCNA. The results were expressed as mean and standard error, and analyzed by ANOVA, considering statistically significant if p≤0.05. RESULTS: There was a significant increase in the expression of undifferentiated cell markers, such as fibronectin (protein present in the extracellular matrix) and CD44 (glycoprotein present in the endothelial cells). However, there was decreased expression of vimentin and PCNA, indicating a possible decrease in the process of cell proliferation after treatment with VEGF165. Markers of differentiated cells, E-cadherin (adhesion protein between myocardial cells), CD24 (protein present in the blood vessels), and alpha-1-actin (specific myocyte marker), showed higher expression in the groups submitted to gene therapy, compared to non-treated group. The value obtained by the relation between alpha-1-actin and vimentin was approximately three times higher in the groups treated with VEGF165, suggesting greater tissue differentiation. CONCLUSION: The results demonstrated the important role of myocytes in the process of tissue remodeling, confirming that VEGF165 seems to provide a protective effect in the treatment of acute myocardial infarct.
No takes yet. Share an insight, caveat, or question.
Garcia et al. (2015) studied Acute myocardial infarction (experimental rat model) (n=40). VEGF165 gene transfer (recombinant DNA plasmid pVEGF165) vs. Untreated infarcted control was evaluated on Immunohistochemical expression index (ou/µm²) of extracellular matrix remodeling, cell differentiation, and proliferation markers (e.g., PCNA in large infarction) (p=0.0006). VEGF165 gene therapy increased the alpha-1-actin to vimentin differentiation ratio roughly 3-fold and reduced PCNA proliferation expression in small and large rat infarcts.
Synapse has enriched 10 related papers. Consider them for comparative context: